Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Vanderbilt University National Institutes of Health (NIH) |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00732069 |
Little is known about how some drugs affect inflammation or clotting factors in people receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they do in people not undergoing hemodialysis or whether they could increase the risk of heart problems. The purpose of the study is to measure certain chemicals in the blood and see how those chemicals may change during hemodialysis when certain drugs are given.
Condition | Intervention | Phase |
---|---|---|
Hemodialysis Renal Dialysis |
Drug: ramipril Drug: valsartan Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Crossover Assignment, Double Blind (Subject, Investigator, Outcomes Assessor), Health Services Research, Pharmacokinetics Study, Randomized |
Official Title: | Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2 |
Estimated Enrollment: | 18 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | August 2010 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan
|
Drug: ramipril
After a washout period, subject will undertake 3 study periods with one of the three treatments: Ramipril initiated at 2.5 mg/d for 2 days followed by 5 mg for a total of nine days
|
2: Active Comparator
After a three week washout period, each subject will be randomized to receive one of the three treatments, placebo, ramipril or valsartan
|
Drug: valsartan
After a three week washout period, each subject will undertake 3 study periods with one of three treatment: Valsartan initiated at 80 mg/d for 2 days followed by 160 mg/d for a total of 9 days
|
3: Placebo Comparator
After a three week washout period, each subject will undertake 3 study periods with one of the three treatments, placebo, ramipril or valsartan
|
Drug: Placebo
After a three week washout period, subject will undertake 3 study periods with one of three treatments: Placebo (inactive pill) for nine days.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Delia M Woods, BSN | 615-322-3371 | delia.woods@vanderbilt.edu |
United States, Tennessee | |
Vanderbilt University Medical Center | Recruiting |
Nashville, Tennessee, United States, 37323 | |
Contact: Delia M Woods, BSN 615-322-3371 delia.woods@vanderbilt.edu | |
Principal Investigator: Nancy J Brown, MD | |
Sub-Investigator: Josh Billings, MD |
Principal Investigator: | Nancy J Brown, MD | Vanderbilt University |
Responsible Party: | Vanderbilt University Medical Center ( Nancy J. Brown, MD ) |
Study ID Numbers: | Fibrinolysis in Dialysis, R01 HL065193-08A2 |
Study First Received: | August 6, 2008 |
Last Updated: | February 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00732069 History of Changes |
Health Authority: | United States: Institutional Review Board |
angiotensin converting enzyme inhibition angiotensin receptor blockade endothelial dysfunction fibrinolysis hemodialysis |
inflammation kallikrein-kinin oxidative stress RAAS |
Kallikreins Angiotensin-Converting Enzyme Inhibitors Stress Cardiovascular Agents Antihypertensive Agents |
Ramipril Valsartan Protease Inhibitors Inflammation |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Valsartan Ramipril Protease Inhibitors |